Waters Corporation (NYSE: WAT), a global leader in analytical laboratory instruments and workflow solutions, has drawn considerable attention from investors as its share price hovers near the $377 level, with the psychologically significant $400 threshold standing as the next major milestone. The stock has traded as high as $414.15 over the past 52 weeks but has since pulled back, leaving market participants to debate whether renewed momentum can carry it back above the $400 mark. With a consensus analyst price target of approximately $413 and multiple Wall Street firms explicitly setting $400 price objectives, the question of whether Waters can reclaim this level is far from academic.
Round numbers carry psychological weight in equity markets, and $400 represents a clear milestone that investors and traders alike monitor. For Waters Corporation, $400 sits at the convergence of multiple Wall Street price targets. Bank of America raised its target to $400 in early June 2026, while Piper Sandler initiated coverage with a Neutral rating and an identical $400 target. Earlier in 2026, Barclays set a $400 target when resuming coverage with an Overweight rating, though the firm has since lifted its objective to $425 following strong quarterly results. This clustering of analyst targets around $400 has made it the most widely referenced price objective for the stock.
From a technical perspective, the stock's 52-week range spans from $275.05 to $414.15, positioning $400 slightly below the midpoint between current levels and the prior peak. Reclaiming $400 would signal that the post-acquisition digestion period is progressing favorably and that institutional buyers are regaining confidence in the company's expanded platform.
Waters Corporation designs, manufactures, and services analytical instruments centered on liquid chromatography, mass spectrometry, and thermal analysis. The company serves pharmaceutical, biotechnology, academic, government, and industrial customers worldwide. In early 2026, Waters completed the acquisition of Becton Dickinson's Biosciences and Diagnostic Solutions businesses, a transformative deal that roughly doubled the company's revenue scale and added flow cytometry, reagents, and clinical diagnostics capabilities to its traditional chromatography franchise.
The company currently carries a market capitalization of approximately $37 billion and generated trailing twelve-month revenue of $3.77 billion, reflecting 26.4% growth largely driven by the acquisition. Waters posted Q1 2026 adjusted earnings per share (EPS) of $2.70, comfortably exceeding the $2.31 consensus estimate, while revenue of $1.27 billion surpassed the high end of management's guidance. The company raised its full-year 2026 adjusted EPS guidance to $14.40–$14.60, implying 10%–11% earnings growth. These results have provided the fundamental backbone for the stock's recovery toward the $400 level.
Several factors support the case for Waters reaching $400 in the near term. First, the BD Biosciences acquisition is already generating early revenue synergies, and management's synergy targets are widely viewed as conservative. Barclays has explicitly noted "plenty of room for upside" to the announced synergy figures, and even base-case projections imply mid-teens EPS growth in future years.
Second, Waters' reorganization into four divisions—analytical sciences, biosciences, advanced diagnostics, and materials sciences—positions the company to capture demand across a broader set of laboratory workflows, from early-stage drug discovery through clinical diagnostics. The recurring revenue stream from consumables and service contracts, which accounts for roughly 38% of sales, adds visibility and stability to the revenue base.
Third, analyst sentiment remains broadly constructive. Of 24 analysts covering the stock, 16 rate it Buy or Strong Buy, 8 rate it Hold, and none recommend selling. The average price target of approximately $413 implies not only a move to $400 but continued upside beyond that level. Recent target increases from Goldman Sachs (to $425), HSBC (to $435), and RBC Capital (initiating at $435) reflect growing conviction in the company's trajectory.
Institutional ownership stands at approximately 94%, with major holders including Vanguard Group, Fundsmith LLP, and Janus Henderson, all of which increased their positions in recent quarters—a signal that professional investors see value at current levels.
The path to $400 is not without obstacles. The stock's trailing P/E ratio exceeds 47, reflecting the acquisition-related accounting impacts that have compressed reported earnings. While the forward P/E of roughly 25 is more reasonable, it still demands consistent execution to justify. Any stumble in the BD integration—whether related to revenue synergy realization, cost management, or cultural integration—could compress the multiple quickly.
Negative free cash flow of approximately $502 million represents another concern, as it raises questions about cash generation capacity during a period of elevated integration spending. The company also carries no dividend, meaning total return depends entirely on price appreciation.
From a technical standpoint, Waters has already tested and retreated from levels above $400, with the 52-week high of $414.15 set in November 2025. The stock's beta of 1.20 indicates above-average sensitivity to broader market movements, meaning a general market downturn or sector rotation away from healthcare and life sciences tools could impede progress toward the $400 target regardless of company-specific fundamentals.
Additionally, the large number of Hold ratings—eight analysts remain on the sidelines—reflects lingering uncertainty about whether the BD integration will deliver the promised value. J.P. Morgan maintains a $370 target, while Deutsche Bank stands at $350, suggesting some analysts see limited upside from current levels.
The analyst community presents a nuanced but broadly positive picture. The consensus rating is a Moderate Buy, with an average 12-month price target of approximately $413, roughly 9.5% above current levels. The most bullish firms include Guggenheim and Bernstein, each with $440 targets, while HSBC and RBC Capital have set $435 objectives. Goldman Sachs recently raised its target to $425, citing confidence in the acquisition thesis.
Notably, the $400 target specifically appears in research from Bank of America (Neutral), Piper Sandler (Neutral), and was Barclays' initial target before being raised. The clustering of targets at and above $400 suggests that the level is viewed as achievable but not necessarily as the ceiling. The critical question for investors is whether Waters can not only reach $400 but sustain a valuation above it—a scenario that likely requires the company to demonstrate at least two consecutive quarters of strong organic growth alongside margin improvement.
Navigating price movements around key levels like $400 can be challenging, even for experienced traders. Tickeron's AI Daily Buy/Sell Signals provide a data-driven solution by using artificial intelligence to continuously monitor thousands of stocks and ETFs, including Waters Corporation. The platform generates Buy, Sell, or Hold signals based on evolving market conditions, technical patterns, and AI-powered analysis, helping traders identify potential opportunities and manage existing positions more efficiently. For investors watching whether WAT can break through the $400 resistance level, these signals offer a timely, objective perspective that complements traditional fundamental and technical research.
The $400 price target for Waters Corporation appears realistically achievable based on the company's strong Q1 2026 earnings performance, upwardly revised guidance, and the early success of the BD Biosciences integration. The clustering of analyst targets at or above $400, combined with zero Sell ratings across 24 analysts, provides meaningful validation. The primary catalysts—continued synergy realization, organic revenue growth in the 6.5%–8.0% range, and margin expansion—are all within management's stated objectives.
However, the stock's elevated trailing valuation, negative free cash flow, and the inherent execution risk of integrating a transformative acquisition warrant caution. The eight Hold ratings on Wall Street reflect legitimate concerns that the current price already discounts much of the near-term good news. For Waters to not only touch $400 but establish it as a support level, investors will likely need to see confirmation that the BD integration is delivering sustainable EPS accretion and that organic growth in the legacy chromatography business remains healthy. The upcoming Q2 2026 earnings report, expected in early August, represents the next major test of this thesis.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, WAT has been closely correlated with A. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if WAT jumps, then A could also see price increases.
| Ticker / NAME | Correlation To WAT | 1D Price Change % | ||
|---|---|---|---|---|
| WAT | 100% | -0.63% | ||
| A - WAT | 68% Closely correlated | +0.71% | ||
| RVTY - WAT | 64% Loosely correlated | -0.32% | ||
| TMO - WAT | 60% Loosely correlated | -1.18% | ||
| BRKR - WAT | 58% Loosely correlated | -2.26% | ||
| CRL - WAT | 56% Loosely correlated | -1.09% | ||
More | ||||